ICJEM
Intercontinental Journal of Emergency Medicine

The Intercontinental Journal of Emergency Medicine aims to publish issues related to all fields of emergency medicine and all specialties involved in the management of emergencies in the hospital and prehospital environment of the highest scientific and clinical value at an international level and accepts articles on these topics.

eISSN: 2980-1400
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Letter to the editor
Hypertensive crisis following mepolizumab in a patient with severe eosinophilic asthma: a letter to the editor
Abstract
A significant method for managing asthma involves the use of interleukin-5 (IL-5) inhibitors such as mepolizumab. In this case, a 52-year-old female patient who developed hypertensive crisis, temporary blurred vision, headache and chest pain after mepolizumab treatment is presented. This case is particularly important as hypertensive crisis accompanied by blurred vision following mepolizumab treatment has not been previously demonstrated in the literature. We present the case of a 52-year-old patient who developed hypertensive crisis after mepolizumab treatment for severe asthma. The patient's clinical condition improved after antihypertensive treatment. The possible effects of inflammatory mediator inhibitors on the human immune system should be further investigated so that their negative effects can be detected at an early stage. We recommend blood pressure monitoring for the first 60 minutes after mepolizumab treatment.

Keywords : Hypertension, interleukin-5, mepolizumab, asthma, immunology

Download Article


1. McGregor MC, Krings JG, Nair P, Castro M. The role of biologics in asthma. Am J Respir Crit Care Med. 2019;199(4):433-445. doi:10.1164/rccm.201810-1944CI
2. Fricker M, Harrington J, Hiles SA, Gibson<strong> </strong>PG. Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma. Allergy. 2024;79(11):3118-3128. doi:10.1111/all.16267
3. Kallieri M, Papaioannou AI, Loukides S. Mepolizumab for severe eosinophilic asthma. Expert Rev Respir Med. 2025:1-13. doi:10.1080/17476348. 2025.2545571
4. Fala L. Nucala (mepolizumab): the first IL-5 antagonist monoclonal antibody approved by the FDA for maintenance treatment of severe asthma. Am Health Drug Benefits. 2016;9(Spec Feature):106-110.
5. Pelaia C, Calabrese C, Vatrella A, et al. Benralizumab: From the basic mechanism of action to its potential use in the biological treatment of severe eosinophilic asthma. Biomed Res Int. 2018;2018:4839230. doi:10. 1155/2018/4839230
6. Korbitz PM, Gallagher JP, Bhogal N, Manatsathit W. A unique case of non-cardiac chest pain caused by mepolizumab: case report and review of the literature. J Neurogastroenterol Motil. 2020;26(1):162-163. doi:10. 5056/jnm19175
Article available in :
Volume 3, Issue 4, 2025
Page : 91-92
https://doi.org/10.51271/ICJEM-0067
Article Information
Received : 21 Tem 2025
Accepted : 11 Eyl 2025
Published : 26 Ara 2025
Corresponding Author :

Oğuzhan Zengin: Department of Internal Medicine, Ankara Bilkent City Hospital, Ankara, Turkiye

[email protected]
Citation : Zengin O, Çamlı H, Göre B, Demir AH, Ateş İ. Hypertensive crisis following mepolizumab in a patient with severe eosinophilic asthma: a letter to the editor. Intercont J Emerg Med. 2025;3(4):91-92.

Read: 91
Download : 81
Cited: 0
_Footer